WO2002045746A2 - Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos - Google Patents
Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos Download PDFInfo
- Publication number
- WO2002045746A2 WO2002045746A2 PCT/CU2001/000010 CU0100010W WO0245746A2 WO 2002045746 A2 WO2002045746 A2 WO 2002045746A2 CU 0100010 W CU0100010 W CU 0100010W WO 0245746 A2 WO0245746 A2 WO 0245746A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- vssp
- vaccine
- cells
- egf
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 49
- 108091007433 antigens Proteins 0.000 title claims abstract description 49
- 239000000427 antigen Substances 0.000 title claims abstract description 48
- 230000002163 immunogen Effects 0.000 title claims abstract description 30
- 230000005847 immunogenicity Effects 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 230000002708 enhancing effect Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims abstract description 95
- 229960005486 vaccine Drugs 0.000 claims abstract description 76
- 150000002270 gangliosides Chemical class 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108010030416 proteoliposomes Proteins 0.000 claims abstract description 26
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 25
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 59
- 239000002671 adjuvant Substances 0.000 claims description 30
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 15
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 7
- 238000010348 incorporation Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 210000003905 vulva Anatomy 0.000 claims description 5
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 208000031662 Noncommunicable disease Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 abstract description 8
- 230000028993 immune response Effects 0.000 abstract description 7
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 5
- 230000003308 immunostimulating effect Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 208000036142 Viral infection Diseases 0.000 abstract description 3
- 230000002458 infectious effect Effects 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 102000001301 EGF receptor Human genes 0.000 description 19
- 108060006698 EGF receptor Proteins 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002434 immunopotentiative effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- -1 aliphatic fatty acid Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 102100030613 Carboxypeptidase A1 Human genes 0.000 description 1
- 102100032936 Carboxypeptidase M Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001297 coherence probe microscopy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000001342 constant potential amperometry Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Definitions
- the present invention relates to the branch of human medicine and especially to protective and / or therapeutic vaccines for infectious, autoimmune and cancer diseases, and particularly provides vaccine compositions that allow the generation or increase of the immune response against little antigens.
- immunogenic Previous Technique The little success achieved so far in the prevention and treatment of a group of infectious diseases, cancer and autoimmune diseases with vaccines is due to combinations of various factors, mainly the low immunogenicity of relevant antigens, the lack of knowledge on how to manipulate the regulation of Immune system and strategies to evade pathogens and tumors, including host immunosuppression.
- Those peptides, polypeptides and proteins (or their corresponding DNA sequences) present in tumors and normal tissues, or associated with pathogens that produce chronic infections by evading the action of the immune system are known within the state of the art as low immunogenic antigens. .
- growth factor receptors with kinase activity in tyrosine residues have been shown to be closely related to the development of tumors and tumor metastases, and their value has been proven in some cases as indicators of poor prognosis in cancer.
- receptors such as the epidermal growth factor receptor (EGF-R) or HER-1, the epidermal growth factor 2 receptor (HER-2), and the derived growth factor receptor of platelets (PDGF-R).
- EGF-R epidermal growth factor receptor
- HER-1 epidermal growth factor receptor
- HER-2 epidermal growth factor 2 receptor
- PDGF-R derived growth factor receptor of platelets
- IAE specific active immunotherapy
- Acquired immunity cells cannot distinguish structures that require an immune response from those that do not and therefore need to be instructed by innate immune system cells.
- An essential link between innate and acquired immunity is provided by the Antigen Presenting Cells (CPA), among which the Dendritic Cells (DC) are the most efficient inducers of both primary and secondary immune responses.
- CPA Antigen Presenting Cells
- DCs are crucial because they are the only CPAs capable of activating virgin T lymphocytes.
- molecules related to innate immunity have been identified that could be considered as a new generation of vehicles and adjuvants, because they have the ability to mature DCs and mediate the cross-presentation of antigens coupled to them.
- HSP thermal stress proteins
- HSP HSP
- researchers have the disadvantage that they must be obtained from the source of origin, for example, from tumors. This makes the procedure laborious and expensive and you never really know who is the antigen that has been responsible for the effect.
- Hartmann, et al. Proc. Nati. Acad. Sci. USA, Vol. 96, pp 9305-9310. 1999
- Hemmi, et al (Nature, Vol. 6813, pp 740-5. 2000)
- Sparwasser, et al. Eur. J. lmmunol. Vol. 12, pp 3591-3597. 2000
- Hochreiter et al. (Int. Arch. Allergy Immunol. No. 124, pp.
- compositions are characterized in that the antigens are chemically modified by the addition of at least one cysteine residue and subsequent conjugation of an aliphatic fatty acid molecule or a hydrophobic peptide. Subsequently, the modified antigens are complexed with a proteasome by dialysis or lyophilization processes. In particular these compositions do not include glycosides. Disclosure of the invention.
- the novelty of the present invention consists in providing formulations that allow to make immunogenic peptides, polypeptides, proteins, their corresponding DNA sequences and white cells of vaccine interest, without the need to introduce structural changes in said antigens, by means of their association with very small proteoliposomes size (Very Small Size Proteoliposomes, VSSP) of the Neisseria meningitidis bacteria, which contain potent innate immunity ligands and gangliosides.
- This invention shows how the immunopotentiating vehicle consists precisely of very small-sized proteoliposomes (VSSP) obtained from the association of the Protein Complex of the External Membrane (CPME) of the Gram-negative bacterium Neisseria meningitidis with gangliosides.
- An object of this invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, white cells or their used as antigens, and very small proteoliposomes (VSSP), which are formed by joining the Complex of Proteins of the External Membrane (CPME) of the bacterium Neisseria meningitidis with gangliosides, by hydrophobic bonds. Additionally it is postulated that these compositions can be formulated alone or in emulsions with the incomplete Freund's adjuvant (AIF) and also be lyophilized. Another object of the invention is to provide immunostimulatory compositions capable of generating antigen-specific immune responses even in immunocompromised hosts, such as those suffering from cancer and chronic viral infections.
- CPME External Membrane
- AIF incomplete Freund's adjuvant
- the administration of the vaccine compositions described in this invention makes it possible to restore the functionality of sectors of their immune system.
- the vaccine compositions described in the present invention constitute a solution to the problem of the immunogenicity of growth factor receptors and their impact on the treatment of tumors, because these receptors with tyrosine kinase activity and the gangliosides that specifically they are associated with these in the form of molecular membrane clusters, they are presented simultaneously to the host's immune system in the context of the danger signals provided by the VSSP, necessary to activate dendritic cells (DC) in a way effective, and produce cross presentation.
- DC dendritic cells
- vaccine compositions in addition to presenting their components to the immune system, simulating the molecular associations in which they naturally occur in tumor cells, make the use of chemical protein conjugation techniques that generate new spurious immunodominant epitopes unnecessary.
- this technological solution allows the use of the complete structures of the receptors, favoring the solution of the problem of the genetic restriction of immunodominance, unlike others that have used derived peptides and that may have more limitations in this regard. More specifically the invention provides vaccine compositions for the treatment of cancer.
- Said vaccine compositions contain as active ingredient one or more receptors of growth factors or their extracellular domains, the latter may or may not contain the transmembrane domains, using as a vaccine vehicle very small-sized proteoliposomes derived from the Neisseria outer membrane protein complex. meningitidis (VSSP) and gangliosides that are specifically associated with these receptors, forming molecular membrane clusters. These vaccine compositions may additionally contain an appropriate adjuvant.
- the vaccine compositions of the invention can be used in the specific active immunotherapy of tumors such as prostate cancer, colon, lung, breast, ovary, head-neck, vulva, bladder, gliomas, as well as in chronic non-communicable diseases. Detailed description of the invention.
- the present invention relates to pharmaceutical compositions to enhance the immunogenicity of low immunogenic antigens, the components of which are: (A) one or more low immunogenic antigens;
- compositions of the invention allow to enhance the immunogenicity of poorly immunogenic antigens, which may be peptides, polypeptides, proteins, or their corresponding nucleic acid sequences, as well as white cells of vaccine interest, or their used, or the mixture thereof.
- growth factor receptors or their extracellular domains can be employed. Such extracellular domains of growth factor receptors may or may not contain their transmembrane region.
- Receptors of growth factors that can be used to increase their immunogenicity are HER-1, HER-2, R-PDGF or any of its variants that contain the extracellular domain with and without transmembrane region.
- the proteoliposomes of the vaccine vehicle of the present invention are obtained from the outer membrane protein complex of a gram-negative bacterium, with Neisseria meningitidis bacteria being preferred, which may be a wild or genetically modified strain.
- the proteoliposomes of the vaccine vehicle with incorporated gangliosides are obtained by hydrophobic incorporation of said gangliosides to the Neisseria meningitidis outer membrane protein complex, the gangliosides GM1, GM3 or their N- variants being used for this purpose. glycolylated.
- compositions of the invention additionally contain an adjuvant, which can be oily in nature or a natural or recombinant polypeptide.
- an adjuvant which can be oily in nature or a natural or recombinant polypeptide.
- the oil-based adjuvant used is preferably the Freund Incomplete Adjuvant or Montanide ISA 51.
- compositions of the invention are useful for the prevention and treatment of cancer, particularly prostate cancer, colon, lung, breast, ovary, head-neck, vulva, bladder, brain, gliomas, as well as chronic non-communicable diseases. It can also be used for the prevention and treatment of infectious diseases of viral and bacterial origin, and within these, it can be used in the treatment of Acquired Immune Deficiency Syndrome, as well as for the treatment of autoimmune diseases.
- the present invention provides formulations that confer immunogenicity to peptides, recombinant or natural proteins, used cell phones, intact cells and nucleic acids, poorly immunogenic.
- Immunostimulatory formulations can be defined as those capable of stimulating both the humoral and the cellular response against a particular antigen.
- these formulations have the peculiar characteristic of rescuing the immunity of immunocompromised individuals, such as those suffering from cancer and chronic viral infections or certain types of autoimmune diseases.
- This invention shows how the immunopotentiating vehicle consists of very small-sized proteoliposomes (VSSP) obtained from the association of the Protein Complex of the External Membrane (CPME) of the Gram-negative bacterium, Neisseria meningitidis with incorporated gangliosides.
- VSSP very small-sized proteoliposomes
- the components of the CPME undergo a dialysis process that lasts between 2 and 15 days, during which glycolylated and / or acetylated gangliosides are incorporated.
- a dialysis process that lasts between 2 and 15 days, during which glycolylated and / or acetylated gangliosides are incorporated.
- gangliosides With the incorporation of gangliosides to the outer membrane complex, a non-vesicular preparation is obtained, of very small molecular size, invisible to the electron microscope, soluble and of high buoyancy.
- VSSPs of the present invention show surprising immunological properties such as a marked ability to mature dendritic cells, and to immunosuppress immunosuppressed patients.
- VSSPs are obtained as described in Cuban patents 131/93 and 130/97, in US patents 5,788,985 and US 6,149,921, as well as in the article Estevez, et al. (Vaccine, Vol. 18, pp 190-197. 1999).
- the antigenic peptides of interest can be synthetic or extracted from various sources.
- the preferred size of the peptides can be between 7 and 25 amino acids, depending on the type of T cell to be stimulated. However, the length can vary between 3 and 50 amino acids.
- the peptides used can be neutral or charged. The hydrophobic nature of the peptides may also vary.
- the present invention establishes that the recombinant proteins used can be expressed in various expression systems such as bacteria, yeasts, plants and higher cells.
- the use of N. meningitidis as an expression system is postulated, where the proteins of interest are expressed in the outer membrane of the bacterium itself. This allows the protein of interest to be directly part of the CPME.
- the expression of the complete protein, or the insertion of any of its polypeptides or peptides in one or more of the outer membrane proteins of Neisseria meningitidis, such as TBP, Opa, Opc and P1 porins, is equally valid. , P2, P3.
- the antigens of the vaccine compositions can be receptors of growth factors with tyrosine kinase activity overexpressed in tumor tissues and, alternatively, their extracellular domains, with or without transmembrane region, and having a relationship specific with gangliosides expressed in the membrane of tumor cells.
- the growth factor receptors referred to in the invention are proteins obtained recombinantly through clones by Polymerase Chain Reaction (PCR) according to regular Molecular Biology procedures (Sambrook J, Fritsch EF, Maniatis T, Molecular Cloning A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, 1989) in expression plasmids in higher cells. Plasmids containing the genes encoding the receptors or their variants are stably transfected into higher cells such as HEK 293 (ATCC CRL 1573), NIH-3T3 (ATCC CRL 1658) and CHO. The receptors or their variants are expressed by the transfected lines in their membranes or are secreted to the supernatant as appropriate.
- PCR Polymerase Chain Reaction
- antigens are extracted from the membrane of the superior cells that express them or from the culture supernatant of said cells and purified by chromatography. Subsequently they are filtered under sterile conditions and lyophilized. They are stored at 4 ° C.
- the optimal amounts of these antigens in vaccine formulations range between 1 ⁇ g and 1000 ⁇ g per dose.
- the VSSP used in vaccine formulations contain gangliosides selected from those that are specifically associated with growth factor receptors forming molecular membrane clusters, this being the case of GM3 and GM1, among others.
- the VSSPs are present in this vaccine composition in a range between 1 ⁇ g and 1000 ⁇ g referring to the amount of gangliosides per vaccine dose.
- the preferred vaccine compositions in this invention which are vaccine preparations containing as growth factor receptor antigens to which they wish to increase their immunogenicity, can be prepared in various ways: a) The growth factor receptors or their extracellular domains (containing or not, transmembrane region) lyophilized (1-100 mg of protein), amounts of VSSP solutions are added, which allow to guarantee a ratio of receptor / ganglioside mass in a range between 0.1 / 1 to 1/1. Mixing by stirring, between 4 ° C and 20 ° C, during a time interval between 5 minutes and 24 hours. This preparation is kept at a temperature of 4 ° C until it is administered to the host. Just before being administered to the host, the preparation described above is mixed by stirring with AIF in volume / volume ratio between 40/60 and
- the volume ratios cover the appropriate range for the type of emulsion desired according to the route of inoculation to the host.
- Another way of proceeding, equally convenient, is to conserve separately containers containing lyophilized growth factor receptors or their extracellular domains (containing or not transmembrane region) and VSSP solutions, at 4 ° C. Just before being administered to the corresponding host, to the growth factor receptors amounts of VSSP solutions are added, the vaccine composition is prepared in the same manner described in part a).
- a third way of proceeding is to combine more than one growth factor receptor or its extracellular domains (containing or not transmembrane region) with the corresponding VSSP solutions in the vaccine composition
- the amounts of each of the antigens in the vaccine composition will be in any proportion that covers the range between 1 ⁇ g and 1000 ⁇ g per vaccine dose.
- the amounts of each of the gangliosides in the form of VSSP in the vaccine composition will be between 1 ⁇ g and 1000 ⁇ g per vaccine dose.
- the growth factor receptors or their extracellular domains that will be part of it are lyophilized in the amounts referred to in the corresponding subsection.
- amounts of VSSP solutions are added to ensure a receptor / ganglioside mass ratio in a range between 0.1 / 1 to 1/1.
- Mixing by stirring, between 4 ° C and 20 ° C, during a time interval between 5 minutes and 24 hours. This preparation is kept at a temperature of 4 ° C until it is administered to the host.
- the preparation described above is mixed by stirring with AIF in volume / volume ratio between 40/60 and
- multiantigenic systems such as cells from established tumor lines or those obtained directly from cancer patients, are also used in the formulations described in the present invention.
- the inactivation of the cells is achieved by the use of gamma radiation or by treatment with Mitomycin C.
- Another equally convenient alternative is the use of oncolysates obtained by mechanical rupture or infection with tumor cell viruses.
- the immunopotentiating preparations of the present invention can be advantageously used in DNA and RNA vaccines. Also the immunogenicity of retro and adenoviral vectors, used as vaccine vehicles, is increased by combining them with the preparations described in the present invention. These vectors contain the genes that code for the antigenic proteins of interest.
- the different immunogenic formulations are obtained by combining the different antigen systems with VSSP previously produced.
- Antigens that are directly introduced recombinantly into the outer membranes of the N. meningitidis bacteria, as well as those that are incorporated into the proteoliposomes during the dialysis process, are already incorporated into the process of obtaining the VSSPs.
- these modified proteoliposomes can also be used with other unincorporated antigens. This allows the preparation of multivalent vaccines.
- the preparations with protein antigens are obtained from mixing between 10 and 1000 ⁇ g of the peptide or antigenic protein with amounts of VSSP that allow to guarantee a ratio of total protein mass / ganglioside in a range between 1 and 3.
- the preparations are preserved at a temperature of 4 ° C until the moment of administration to the host. Another way of proceeding, equally convenient, is to keep the antigenic solutions and the VSSP solutions separately, at 4 ° C, and mix them just before being administered.
- Nucleic acid formulations are obtained by directly mixing the VSSPs with the DNA or RNA solutions. The mixing process is carried out at 4 ° C, guaranteeing a ratio of 2-100 ⁇ g of nucleic acid per 0.1 mg of ganglioside in VSSP. This method is feasible due to the absence of nucleases in VSSP preparations.
- live viral vectors vaccinia virus, fowlpox or others
- VSSPs are administered intramuscularly, subcutaneously, intradermally, orally or intranasally, between 12 hours before and 12 hours after administering the viral vector.
- the preparations with white cells of interest or their used ones are obtained first by precipitating the respective cultures by centrifugation and then resuspending the cell precipitate in amounts of VSSP that allow to guarantee a ratio between 10 3 and 5x10 6 cells per 0.1 mg of ganglioside.
- These quantities are mixed directly by stirring, between 4 ° C and 20 ° C, for a time interval between 5 and 24 hours.
- the preparations are stored at a temperature of 4 ° C until the time of administration to the host.
- Another way of proceeding, equally convenient, is to keep separately the cell suspensions or their corresponding used and the VSSP solutions, at 4 ° C, and mix them just before being administered.
- the preparations described in the present invention, in which the antigens are mixed or incorporated into the VSSPs, can be administered alone or emulsified with incomplete Freund's adjuvant (AIF).
- Emulsions are prepared just before being administered to the host. Each preparation is mixed by stirring with the adjuvant in volume / volume ratio between 40/60 and 60/40, for a time interval between 10 and 30 minutes, at room temperature.
- the volume ratios cover the appropriate range for the type of emulsion desired according to the route of inoculation to the host.
- the described preparations in which the antigens are mixed or incorporated into the VSSPs, are lyophilized before being administered alone or emulsified with incomplete Freund's adjuvant.
- the vaccine compositions of the present invention can be introduced into the patient parenterally (intramuscularly, intradermally, subcutaneously) or by direct application on mucous membranes. Examples of realization.
- Example 1 Obtaining an antigen of the vaccine composition composed of extracellular domain (ECD) from murine EGF-R (ECD-EGF-Rm).
- the gene encoding the ECD-EGF-Rm was amplified using the PCR technique, from complementary DNA (cDNA) of mouse liver.
- the PCR was performed by mixing 1 ⁇ g of cDNA with, 10 pmoles of each specific primer. Subsequently 0.2 mMolar of each dNTP and 1 U of Taq polymerized was added. 30 cycles of PCR were performed with temperatures of 9 ° C, 1 min. (except in the first cycle that were 3 min.); 56 ° C, 1 min .; 72 ° C, 1 min. and 30 sec. (except in the last cycle that was 5 min.).
- the amplified gene was cloned into the expression vector in superior pcDNA3 cells (AmpTori, ColE ori, CMV-Promoter, SV40 or ⁇ , SV40pa, Neomycin, Invitrogen), and subsequently the HEK-293 line cells were stably transfected with this plasmid. Transfection was carried out by conventional methods and the cells were grown in a selective medium.
- the ECD-EGF-Rm is obtained from the supernatant of the HEK-293 / ECD-EGF-Rm line that stably expresses the ECD-EGF-Rm.
- the ECD-EGF-Rm obtained in the culture supernatant is purified by affinity chromatography techniques, coupling the ligand to the matrix (Affinity Chromatography principies and methods 3:12, Pharmacia fine Chemicals); It is subsequently filtered under sterile conditions, and lyophilized.
- Example 2 Obtaining a vaccine composition comprising ECD-EGF-Rm, VSSP-GM3 and incomplete Freund's adjuvant (AIF), combining all components just before administration.
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including the incorporated GM3 ganglioside were obtained as referred to in US Patent No. 6,149,921.
- the OMPC complex of N. meningitidis provided by the "Carlos J. Finlay” Institute (C. Campa et al EP 301992) was employed. 10 mg of this OMPC complex is dispersed in a solution of 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate, also containing 10 mg of NAcGM3, by gentle mixing overnight at 4 ° C.
- the separation of the soluble complex OMPC-NGCGM3 from the detergents was carried out by dialysis, for 14 days, using a 3.5 Kda membrane.
- the dialysate was ultracentrifuged at 100,000 g for 1 h and the immunogen present in the supernatant was sterilized by filtration.
- the degree of incorporation of ganglioside into protein was determined using the Bio-Rad reagent for proteins and resorcinol for sialic acid. In this way an incorporation of 1 mg of NGcGM3 per mg of OMPC is obtained.
- the amount of the vaccine vehicle previously prepared is 120 ⁇ g, based on the amount of gangliosides incorporated in the proteoliposomes per vaccine dose.
- ECD-EGF-Rm 1 mg was lyophilized and stored at 4 ° C until the time of immunization.
- 2.4 mg of VSSP-GM3 referred to amount of ganglioside
- AIF 1 mL of AIF
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside were obtained as referred to in US Patent No. 6,149,921.
- the amount of vaccine vehicle used was 120 ⁇ g referred to the amount of gangliosides per vaccine dose.
- To prepare the immunogen 1 mg of ECD-EGF-Rm was lyophilized, and then 2.4 mg of VSSP-GM3 (referring to the amount of ganglioside incorporated) was added, in a volume of 1 mL. Both components were mixed at room temperature for 15 minutes and stored at 4 ° C until the time of immunization. Just before administration to the mice, 1 mL of AIF was added and the mixing was performed by stirring at room temperature for 20 minutes.
- Example 4. Obtaining a combined vaccine comprising ECD-HER-1, ECD-HER-2, VSSP-GM3 and AIF.
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside were obtained as referred to in US Patent No. 6,149,921.
- the amount of vaccine vehicle used was 120 ⁇ g referred to the amount of gangliosides incorporated in the proteoliposomes per vaccine dose.
- ECD-HER-1 and 1 mg of ECD-HER-2 were lyophilized together, and stored at 4 ° C until the time of immunization.
- 2.4 mg of VSSP-GM3 (referred to amount of ganglioside) was added in a volume of 1 mL. All components were mixed at room temperature for 15 minutes. Subsequently, 1 mL of AIF was added and the mixture was made by stirring at room temperature for 20 minutes.
- Example 5 Induction of specific immune response to autologous R-EGF by the vaccine composition.
- mice of the C57BL / 6 line were immunized with the vaccine composition containing ECD-EGF-Rm / VSSP-GM3 and AIF, prepared as described in example 2.
- the immunogen dose was 50 ⁇ g per mouse based on quantity of antigen in the composition.
- the immunization schedule followed comprised three doses intramuscularly every fifteen days, with blood drawn on days 0, 21, 35 and 56 after the first immunization (Group II).
- a group of mice of the same line immunized with 50 ⁇ g of ECD-EGF-Rm chemically conjugated to KLH and adjuvant in Freund's Complete Adjuvant (ACF) and AIF was used, following the same immunization schedule (Group I).
- the sera obtained were tested by ELISA for recognition to ECD-EGF-Rm.
- the ELISA was performed by coating the plate with 10 ⁇ g / mL ECD-EGF-Rm. After blocking the plate with PBS / 5% calf serum, sera from the immunized animals and controls were incubated at different dilutions. A mouse anti-IgG antibody conjugate (Fe-specific) with alkaline phosphatase (Sigma) was then added. All the aforementioned incubations were performed for 1 hour at 37 ° C and after each of the mentioned steps three washes were performed with PBS / 0.05% Tween 20.
- the reaction was developed with the addition of 1 mg / mL of substrate (p-nitrophenyl phosphate) in diethanolamine buffer, pH 9.8.
- substrate p-nitrophenyl phosphate
- the absorbance at 405 nm was measured in an ELISA reader at 30 min. 100% of the mice immunized with the vaccine composition of the invention developed a specific antibody response against ECD-EGF-Rm, which increased during the course of immunizations, reaching titres of up to 1/160000, while the Preimmune sera did not recognize ECD-EGF-Rm.
- the isotype of the antibody response developed was primarily of the IgG type.
- the subclass distribution of the induced antibody response was determined by ELISA. 20.21% of the antibodies were lgG2a, 36.03% lgG1 and 38.93% was lgG2b, showing a shift towards the Th1 response pattern with respect to the reference group ( Figure 1).
- the present vaccine composition is compared with a composition in which the ECD-EGF-Rm is chemically coupled to KLH, and where uses ACF as an adjuvant, the antibody titres induced by the preparation are superior, and the subclass distribution tends more to a Th1 pattern, proving favorable for the efficacy of said vaccine.
- mice immunized with ECD-EGF-Rm ⁇ / SSP-GM3 / AIF showed no signs of clinical toxicity, and the biochemical tests performed on the sera of these animals showed no differences with those performed on sera from non-immunized animals (Table 1) .
- A431 line cells (10,000 cells / well) expressing the human epidermal growth factor receptor were incubated with preimmune serum from C57BL / 6 mice diluted 1/5 (A), ior egf-r3 monoclonal antibody against EGF-R as a positive control at a concentration of 10 ⁇ g / mL (B) and serum of immunized C57BL / 6 mice diluted 1/5 (C), for 30 minutes at room temperature.
- the excess of antibodies not bound to the receptor or bound in a non-specific way was removed by washing with 0.5% buffered phosphate / calf serum solution.
- A431 line cells (3x10 6 cells) were incubated with 51 Cr radioactive sodium chromate for 1h, and the excess radioactive salts were removed by three washes with culture medium.
- Cells loaded with 51 Cr were incubated with: i) 50 ⁇ g / mL of the ior-t3 monoclonal antibody (AcM against CD3, as a negative control) ii) 50 ⁇ g / mL of the ior egf-r3 monoclonal antibody (AcM against EGF -R as a positive control) iii) preimmune serum from C57BL / 6 mice diluted 1/20 iv) serum from C57BL / 6 mice immunized with ECD-HER-1 / VSSP-GM3 / AIF diluted 1/20
- Sera from mice immunized with the vaccine preparation referred to in the patent were tested for their ability to inhibit the binding of EGF to its receptor on the membrane of A431 cells.
- A431 cells were grown in culture plates until confluence. Once confluent, an immune serum pool was added at different dilutions (1/5, 1/10, 1/20, 1/40) and then EGF- 125 I was added at a rate of 100,000 cpm / well. The volume of each well was completed up to 500 ⁇ L of PBS / 1% BSA in each well. The plates were incubated at room temperature for 1 hour and after this time the reaction was stopped by adding 2 mL of cold 1% PBS / BSA.
- mice of the C57 / BL6 line, immunized with ECD-EGF-RmVSSP-GM3 / AIF were transplanted with 100,000 Lewis cells intramuscularly and were observed to determine the time Survival Lewis cells are derived from a lung adenocarcinoma of murine origin that express EGF-R. The survival of these mice was compared with that of a group immunized with ECD-EGF-Rm / ACF (three doses of 50 ⁇ g every fifteen days subcutaneously).
- Example 10 Obtaining a vaccine composition containing the chimeric monoclonal antibody P3 (AcMq P3), VSSP (GM3) and AIF.
- the VSSPs (GM3) were stored at a concentration of 4.8 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- a solution containing 2 mg / mL of the chimeric AcM P3 (US Patent No. 5,817,53) in saline phosphate buffer solution was mixed with the VSSP preparation (GM3) in a 1/1 (v / v) ratio.
- the mixing process was performed by magnetic stirring at room temperature for 15 min.
- the IDA was added in a 1/1 (v / v) ratio.
- the mixture was stirred at room temperature for 15 minutes, until the emulsion was achieved.
- a solution containing 2 mg / mL of AcMq P3 in saline phosphate buffer solution was mixed with the VSSP (GM3) in a 1/1 (v / v) ratio.
- the mixing process was performed by magnetic stirring at room temperature for 15 min. and the resulting solution was sterilized by filtration through 0.2 ⁇ m cellulose acetate membranes.
- the preparation was stored at 4 ° C for a period of up to one year.
- the preparation was added to the AIF in a 1/1 (v / v) ratio and emulsification was performed by stirring at room temperature for 15 minutes.
- Example 11 Obtaining a vaccine composition containing a peptide from the heavy chain variable region of AcMq P3 (CDR3 / VH-P3) and VSSP (GM3).
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside [VSSP (GM3)], were obtained as described in Cuban patent 130/97 and in US patent 6,149,921.
- the VSSPs (GM3) were stored at a concentration of 4.8 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- the immunogen was first prepared by dissolving lyophilized CDR3 VH-P3 peptide in saline phosphate buffer solution until a concentration of 4 mg / mL was achieved. Subsequently it was mixed with the VSSP preparation (GM3) in a 1/1 (v / v) ratio. The mixing process was performed by magnetic stirring at room temperature for 15 min.
- lyophilized CDR3 VH-P3 peptide was first dissolved in saline phosphate buffer until a concentration of 4 mg / mL was achieved. Subsequently it was mixed with the VSSP preparation (GM3) in a 1/1 (v / v) ratio. The mixing process was performed by magnetic stirring at room temperature for 15 min. and the resulting solution was sterilized by filtration through 0.2 ⁇ m cellulose acetate membranes. After a dosing, packaging and sealing process the preparation was stored at 4 ° C for a period of up to one year.
- Example 12 Obtaining a vaccine composition containing a melanoma oncolysate B16, VSSP (GM3) and AIF.
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside [VSSP (GM3)], were obtained as described in Cuban patent 130/97 and in US patent 6,149,921.
- the VSSPs (GM3) were stored at a concentration of 2.4 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- a suspension of B16 murine melanoma line cells 50x10 6 cells / mL was subjected to 5 freeze / thaw cycles, alternating incubations in liquid nitrogen baths and in distilled H 2 O baths at 37 ° C.
- the resulting cell lysate was centrifuged at 500 xg for 10 minutes.
- the resulting pellet was resuspended in VSSP (GM3) guaranteeing a proportion of cell pellet corresponding to 10 x 10 6 cells per 2.4 mg of GM3 in VSSP.
- the mixture was stirred for 10 minutes at room temperature.
- the preparation was then added to the IDA in a 1/1 (v / v) ratio.
- the mixture was stirred at room temperature for approximately 15 minutes, until the emulsion was achieved.
- Example 13 Obtaining a vaccine composition containing melanoma cells B16, VSSP (GM3) and AlF.
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex, including GM3 ganglioside [VSSP (GM3)] were obtained as described in Cuban patent 130/97 and in US patent 6,149,921.
- the VSSPs (GM3) were stored at a concentration of 2.4 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- To prepare the immunogen a suspension of B16 murine melanoma line cells (50 x 10 6 cells / mL) was centrifuged at 300 xg for 10 minutes.
- the cell pellet was resuspended with the VSSPIGM3) guaranteeing a ratio of 10 x 10 6 cells per 2.4 mg of GM3 in VSSP.
- the mixture was stirred for 10 minutes at room temperature.
- the preparation was then added to the AlF in a 1/1 (v / v) ratio.
- the mixture was stirred at room temperature for approximately 15 minutes, until the emulsion was achieved.
- Example 14 Obtaining a vaccine composition containing a plasmid with the gene encoding the extracellular domain of the human EGF receptor (ECD-HER1), VSSP (GM3) and AlF.
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside [VSSP (GM3)], were obtained as described in Cuban patent 130/97 and in US patent 6,149,921.
- the VSSPs (GM3) were stored at a concentration of 4.8 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- the vector to insert the DNA of interest was the expression plasmid in mammals pcDNA3, which contains the origin of SV40 replication and the immediate early promoter of human cytomegalovirus (pCMVIT). In this plasmid the gene encoding the extracellular domain of the human EGF receptor (ECD-HER1) was inserted.
- the resulting plasmid (ECD-HER1 / pcDNA3) was used in the preparation of the immunogen.
- the ECD-HER1 / pcDNA3 plasmid solution was adjusted to a concentration of 2 mg / mL in saline phosphate buffer. Subsequently it was mixed with the VSSP preparation (GM3) in a 1/1 (v / v) ratio. The mixture was performed by stirring at room temperature for 5 min. Then the preparation was added to the AlF in a 1/1 (v / v) ratio. The mixture was stirred at room temperature for approximately 15 minutes, until the emulsion was achieved.
- Example 15 In vitro induction of dendritic cell maturation by the VSSP preparation (GM3).
- Human dendritic cells were obtained from monocytes isolated from peripheral blood that were cultured, for 7 days, in the presence of recombinant human GM-CSF (hr) (50 ng / ml) and hr-IL4 (1000 U / ml). On the 7th day the dendritic cells obtained were exposed or not, for 18 hours, to the VSSPs (GM3) (1 ⁇ g / mL).
- GM3 recombinant human GM-CSF
- hr-IL4 1000 U / ml
- mice of the C57BL / 6 line were immunized with the vaccine composition referred to in Example 10.
- 50 ⁇ g of the chimeric monoclonal was inoculated in each injection, applying 2 doses (one every 14 days) intramuscularly. 21 days after the first immunization serum samples were taken.
- a group of mice of the same strain immunized in the same manner with the AcMq P3 adjuvant in AlF or Alumina was used. The sera obtained were tested by ELISA to determine the presence of anti-AcMq P3 antibodies.
- mice immunized with the vaccine composition described in the present invention developed specific IgG antibody levels against the AcMq P3, higher than those of the reference groups. (Table 3).
- Example 17 Induction of specific proliferative cell response to the CDR3 / VH-P3 peptide associated with the administration of the vaccine composition.
- mice of the C57BL / 6 line were immunized with the vaccine composition described in Example 11. 100 ⁇ g of the peptide was inoculated in each injection, 4 doses (one every 14 days) being applied intramuscularly. A group of mice of the same strain immunized in the same manner with the CDR3 / VH-P3 peptide adjuvant in AlF or Alumina was used as reference. 7 days after the last dose the inguinal lymph nodes were removed from the animals and lymphocytes were isolated by perfusion of the organ. Lymphocytes were cultured for 96 hours with the CDR3 ⁇ / H-P3 peptide (50 ⁇ g / mL).
- Example 18 Induction of specific cytotoxic cellular response to ECD-mEGFR associated with the administration of the vaccine composition containing
- Proteoliposomes derived from the Neisseria meningitidis outer membrane protein complex including GM3 ganglioside [VSSP (GM3)], were obtained as described in Cuban patent 130/97 and in US Pat.
- GM3 ganglioside [VSSP (GM3)] were obtained as described in Cuban patent 130/97 and in US Pat.
- VSSPs (GM3) were stored at a concentration of 2.4 mg / mL in Tris / HCI solution pH 8.9 and at a temperature of 4 ° C, until used.
- the viral vector to insert the DNA of interest was the Avian Smallpox Virus (FPV).
- FPV Avian Smallpox Virus
- ECD-mEGFR murine EGF receptor extracellular domain
- the solution of ECD-mEGFR / FPV recombinant vector was adjusted to a concentration of 10 8 pfu / mL.
- the VSSP emulsion (GM3) was prepared by adding the vehicle solution to the AlF in a 1/1 (v / v) ratio. The mixture was stirred at room temperature for approximately 15 minutes.
- mice were immunized with 200 ⁇ L of the ECD-mEGFR / FPV solution intraperitoneally and with 100 ⁇ L of VSSP (GM3) / AIF intramuscularly, consecutively.
- GM3 ECD-mEGFR / FPV solution
- STFS saline phosphate buffer solution
- T cells were stimulated for 5 days with bone marrow derived dendritic cells (bmDC), previously pulsed with the immunodominant peptide of the ECD-mEGFR 'NYGTNRTGL', in a 10: 1 ratio (T: bmDC) and in the presence of IL- 2 (50 u / mL).
- bmDC bone marrow derived dendritic cells
- IL- 2 50 u / mL
- Example 19 Immunorestaurant properties of the VSSP vaccine vehicle.
- the VSSP vaccine vehicle, described in this invention was administered intramuscularly (im) to patients with metastatic melanoma in the context of a trial.
- Clinical Phase 1. Patients received 9 doses (200 ⁇ g of NGcGM3 in VSSP) within 6 months. The first 5 doses were administered in the first 2 months and the remaining 4 were given monthly. Blood was taken from the patients on day 0 (before administering the first dose) and on day 56 (fifth dose). In parallel, blood was taken from 8 healthy volunteers. From these samples the corresponding peripheral mononuclear cells (CMP) were obtained by the Ficoll gradient method and the% of CD3 +, CD4 + and CD8 + cells were determined by flow cytometry. As shown in Table 6, the relative expression of the CD3, CD4 and CD8 T cell markers, coming from the CMP of the 3 patients taken to exemplify, is lower than the average of healthy donor expression in the day 0.
- CMP peripheral mononuclear
- CD4 and CD8 in the CMP of the same patients were normalized by day 56 or after receiving 4 injections of VSSP (NGcGM3).
- FIG. 1 Subclass distribution of antibodies induced from immunization with ECD-EGF-Rm / VSSP-GM3 / AIF. Sera from C57BL / 6 mice immunized with ECD-EGF-Rm / KLH / ACF (I) or ECD-EGF-Rm / VSSP-GM3 / AIF (II) were tested by ELISA for the determination of subclass distribution of induced IgG by immunization.
- Figure 2. Recognition of sera from mice immunized with DEC-HER-1 ⁇ / SSP-GM3 / AIF to cells expressing EGF-R.
- A431 line cells were incubated with preimmune serum from C57BL / 6 mice (A), ior egf-r3 monoclonal antibody as a positive control (B) and serum from immunized C57BL / 6 mice (C).
- A preimmune serum from C57BL / 6 mice
- B ior egf-r3 monoclonal antibody
- C serum from immunized C57BL / 6 mice
- A431 cells loaded with 51 Cr were incubated with complement and: I) ior-t3 monoclonal antibody (against CD3, as negative control), II) ioEGF-R-r3 monoclonal antibody (against EGF-R, as positive control), III) preimmune serum of C57B1 / 6 mice, IV) serum of C57BL / 6 mice immunized with ECD-HER-1 / VSSP-GM3 / AIF V) Equal number of cells that were used with detergents in the previous points as a measure of Total incorporation of 51 Cr. The results are presented in% specific lysis.
- Figure 4 Neutralizing capacity of sera from mice immunized with ECD-HER-1 / VSSP-GM3 / AIF.
- a 431 cells were incubated with dilutions 1/5, 1/10, 1/20 and 1/40 of a pool of sera from mice immunized with ECD-HER-1 / VSSP-GM3 / AIF or with the same dilutions of a pool of preimmune sera.
- EGF- 125 I (100000 com) was added in each well and total binding was measured by incubating the cells with EGF125I.
- CPMs were measured in a gamma radiation counter.
- Figure 5 Survival of mice immunized with ECD-EGF-Rm / VSSP-GM3 / AIF transplanted with Lewis tumor.
- mice of strain C57BL / 6 immunized as referred to in Example 9 were transplanted with 100,000 Lewis Tumor cells and observed to measure survival.
- mice of the same strain were immunized with ECD-EGF-Rm / ACF.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002547529A JP4210519B2 (ja) | 2000-12-06 | 2001-12-06 | 低免疫原性抗原の免疫原性を増強する医薬組成物 |
AU2151902A AU2151902A (en) | 2000-12-06 | 2001-12-06 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
EA200300640A EA005138B1 (ru) | 2000-12-06 | 2001-12-06 | Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью |
MXPA03005032A MXPA03005032A (es) | 2000-12-06 | 2001-12-06 | Composiciones farmaceuticas para potenciar inmunogenicidad de antigenos poco inmunogenicos. |
EP01999387A EP1356822B1 (en) | 2000-12-06 | 2001-12-06 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
AU2002221519A AU2002221519B2 (en) | 2000-12-06 | 2001-12-06 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
AT01999387T ATE485833T1 (de) | 2000-12-06 | 2001-12-06 | Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern |
DK01999387.2T DK1356822T3 (da) | 2000-12-06 | 2001-12-06 | Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener |
CA2431188A CA2431188C (en) | 2000-12-06 | 2001-12-06 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
DE60143363T DE60143363D1 (de) | 2000-12-06 | 2001-12-06 | Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern |
BRPI0116013-3 BRPI0116013B8 (pt) | 2000-12-06 | 2001-12-06 | composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica |
KR1020037007634A KR100850473B1 (ko) | 2000-12-06 | 2001-12-06 | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 |
NZ526282A NZ526282A (en) | 2000-12-06 | 2003-06-04 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
HK04106497A HK1063726A1 (en) | 2000-12-06 | 2004-08-30 | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU285/2000 | 2000-12-06 | ||
CU20000285A CU23000A1 (es) | 2000-12-06 | 2000-12-06 | Composiciones vacunales para la inmunoterapia activa específica del cáncer |
CU167/2001 | 2001-07-12 | ||
CU20010167A CU23009A1 (es) | 2001-07-12 | 2001-07-12 | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002045746A2 true WO2002045746A2 (es) | 2002-06-13 |
WO2002045746A3 WO2002045746A3 (es) | 2002-12-27 |
Family
ID=38812545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2001/000010 WO2002045746A2 (es) | 2000-12-06 | 2001-12-06 | Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
Country Status (20)
Country | Link |
---|---|
US (1) | US7776342B2 (es) |
EP (1) | EP1356822B1 (es) |
JP (1) | JP4210519B2 (es) |
KR (1) | KR100850473B1 (es) |
CN (1) | CN1291755C (es) |
AR (1) | AR031638A1 (es) |
AT (1) | ATE485833T1 (es) |
AU (2) | AU2151902A (es) |
BR (1) | BRPI0116013B8 (es) |
CA (1) | CA2431188C (es) |
DE (1) | DE60143363D1 (es) |
DK (1) | DK1356822T3 (es) |
EA (1) | EA005138B1 (es) |
HK (1) | HK1063726A1 (es) |
MX (1) | MXPA03005032A (es) |
NZ (1) | NZ526282A (es) |
PE (1) | PE20020572A1 (es) |
UY (1) | UY27059A1 (es) |
WO (1) | WO2002045746A2 (es) |
ZA (1) | ZA200304411B (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005032585A1 (es) * | 2003-10-09 | 2005-04-14 | Centro De Ingenieria Genetica Y Biotecnologia | Composiciones farmacéuticas que contienen antígenos del virus de papiloma humano |
WO2015014327A1 (es) * | 2013-08-02 | 2015-02-05 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1367395A1 (de) * | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
US8147840B2 (en) * | 2004-05-14 | 2012-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
KR101940826B1 (ko) * | 2010-12-22 | 2019-01-21 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 소종 동물에서의 증대된 면역 반응 |
KR101323845B1 (ko) * | 2011-01-21 | 2013-10-31 | 광주과학기술원 | 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물 |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
RU2747857C2 (ru) * | 2013-03-15 | 2021-05-17 | Ин3Био Лтд. | Самособирающиеся синтетические белки |
US10105306B2 (en) * | 2013-09-17 | 2018-10-23 | Bestop Group Holdings Limited | Method of preparing a growth factor concentrate |
HK1194912A2 (en) * | 2013-09-17 | 2014-10-24 | Bestop Group Holdings Ltd | Growth factor concentrate and the use thereof |
JP6609565B2 (ja) * | 2014-03-11 | 2019-11-20 | ユニヴェルシテ デクス−マルセイユ | 細胞膜ガングリオシドと相互作用するキメラペプチド |
EP3597214A1 (en) | 2017-03-15 | 2020-01-22 | Centro de Inmunologia Molecular | Method for the treatment of patients with carcinomas |
WO2019067673A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | ERBB PEPTIDE-BASED PHARMACEUTICAL AND VACCINE COMPOSITIONS AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER |
CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
CN109865137A (zh) * | 2019-01-23 | 2019-06-11 | 天德悦(北京)生物科技有限责任公司 | 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0283443A2 (en) * | 1987-02-18 | 1988-09-21 | Istituto Farmacoterapico Italiano S.P.A. | Process for extracting membrane antigens having immunogenic properties from human neoplastic cells and products thereby obtained |
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
WO1999036085A1 (en) * | 1998-01-16 | 1999-07-22 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
EP0651656A1 (en) | 1992-07-08 | 1995-05-10 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22420A1 (es) | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
-
2001
- 2001-11-29 PE PE2001001202A patent/PE20020572A1/es not_active Application Discontinuation
- 2001-12-05 AR ARP010105662A patent/AR031638A1/es not_active Application Discontinuation
- 2001-12-06 JP JP2002547529A patent/JP4210519B2/ja not_active Expired - Lifetime
- 2001-12-06 CN CNB018215602A patent/CN1291755C/zh not_active Expired - Lifetime
- 2001-12-06 UY UY27059A patent/UY27059A1/es unknown
- 2001-12-06 EP EP01999387A patent/EP1356822B1/en not_active Expired - Lifetime
- 2001-12-06 DK DK01999387.2T patent/DK1356822T3/da active
- 2001-12-06 AU AU2151902A patent/AU2151902A/xx active Pending
- 2001-12-06 AT AT01999387T patent/ATE485833T1/de active
- 2001-12-06 EA EA200300640A patent/EA005138B1/ru not_active IP Right Cessation
- 2001-12-06 WO PCT/CU2001/000010 patent/WO2002045746A2/es active IP Right Grant
- 2001-12-06 AU AU2002221519A patent/AU2002221519B2/en not_active Expired
- 2001-12-06 MX MXPA03005032A patent/MXPA03005032A/es active IP Right Grant
- 2001-12-06 CA CA2431188A patent/CA2431188C/en not_active Expired - Lifetime
- 2001-12-06 KR KR1020037007634A patent/KR100850473B1/ko active IP Right Grant
- 2001-12-06 US US10/003,463 patent/US7776342B2/en active Active
- 2001-12-06 BR BRPI0116013-3 patent/BRPI0116013B8/pt not_active IP Right Cessation
- 2001-12-06 DE DE60143363T patent/DE60143363D1/de not_active Expired - Lifetime
-
2003
- 2003-06-04 NZ NZ526282A patent/NZ526282A/en not_active IP Right Cessation
- 2003-06-05 ZA ZA200304411A patent/ZA200304411B/en unknown
-
2004
- 2004-08-30 HK HK04106497A patent/HK1063726A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0283443A2 (en) * | 1987-02-18 | 1988-09-21 | Istituto Farmacoterapico Italiano S.P.A. | Process for extracting membrane antigens having immunogenic properties from human neoplastic cells and products thereby obtained |
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
WO1999036085A1 (en) * | 1998-01-16 | 1999-07-22 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
Non-Patent Citations (1)
Title |
---|
FRANCISCO ESTEVEZ ET AL.: "Enhancement of the Immune Response to Poorly Immunogenic Glangliosides after Incorporation into Very Small Size Proteotipo somer (USSP)" VACCINE, vol. 18 (2000), páginas 190-197, XP002195653 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005032585A1 (es) * | 2003-10-09 | 2005-04-14 | Centro De Ingenieria Genetica Y Biotecnologia | Composiciones farmacéuticas que contienen antígenos del virus de papiloma humano |
WO2015014327A1 (es) * | 2013-08-02 | 2015-02-05 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
AU2014298978B2 (en) * | 2013-08-02 | 2019-05-23 | Centro De Inmunologia Molecular | Divalent vaccine compositions and the use thereof for treating tumours |
EA034194B1 (ru) * | 2013-08-02 | 2020-01-16 | Сентро Де Инмунологиа Молекулар | Вакцинная композиция и ее применение для лечения злокачественных опухолей |
Also Published As
Publication number | Publication date |
---|---|
CN1291755C (zh) | 2006-12-27 |
EP1356822B1 (en) | 2010-10-27 |
JP2004523494A (ja) | 2004-08-05 |
KR100850473B1 (ko) | 2008-08-07 |
ATE485833T1 (de) | 2010-11-15 |
BR0116013A (pt) | 2004-01-06 |
DE60143363D1 (de) | 2010-12-09 |
UY27059A1 (es) | 2002-04-26 |
HK1063726A1 (en) | 2005-01-14 |
BRPI0116013B8 (pt) | 2021-05-25 |
NZ526282A (en) | 2005-01-28 |
ZA200304411B (en) | 2004-07-29 |
AR031638A1 (es) | 2003-09-24 |
KR20030061838A (ko) | 2003-07-22 |
EA005138B1 (ru) | 2004-12-30 |
CN1484532A (zh) | 2004-03-24 |
CA2431188C (en) | 2010-09-07 |
PE20020572A1 (es) | 2002-07-31 |
AU2151902A (en) | 2002-06-18 |
MXPA03005032A (es) | 2004-09-10 |
AU2002221519B2 (en) | 2006-11-23 |
DK1356822T3 (da) | 2011-02-07 |
US20020136735A1 (en) | 2002-09-26 |
CA2431188A1 (en) | 2002-06-13 |
WO2002045746A3 (es) | 2002-12-27 |
BRPI0116013B1 (pt) | 2018-07-24 |
EP1356822A2 (en) | 2003-10-29 |
JP4210519B2 (ja) | 2009-01-21 |
US7776342B2 (en) | 2010-08-17 |
EA200300640A1 (ru) | 2003-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002045746A2 (es) | Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos | |
US7794729B2 (en) | Methods and compositions for immunotherapy of cancer | |
JP4713638B2 (ja) | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン | |
ES2262242T3 (es) | Uso de ligandos de mhc de clase ii como adyuvantes para la vacunacion y lag-3 en el tratamiento del cancer. | |
KR20120098919A (ko) | 암의 치료제 | |
JP2004523494A6 (ja) | 低免疫原性抗原の免疫原性を増強する医薬組成物 | |
ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
US11077177B2 (en) | Universal cancer vaccine | |
ES2286104T3 (es) | Vacuna contra tumores especificos del riñon dirigida contra el antigeno g-250 del tumor de riñon. | |
Livingston | Active specific immunotherapy in the treatment of patients with cancer | |
CN111295200A (zh) | 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒 | |
US8003093B2 (en) | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen | |
ES2353857T3 (es) | Composiciones farmacéuticas que mejoran la inmunogenicidad de antígenos poco inmunogénicos. | |
JP4223813B2 (ja) | 免疫増強特性を有するムチンペプチド | |
Kinzler et al. | Cancer vaccines | |
WO2015130488A2 (en) | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection | |
WO2022083805A1 (es) | Antígeno quimérico que comprende el dominio extracelular de pd-l1 | |
CN113318225A (zh) | 肿瘤免疫增强剂及其制法和应用 | |
RU2420311C2 (ru) | Вакцина на основе в-клеток, нагруженных лигандом т-клеток-природных киллеров и антигеном | |
COCHLOVIUS et al. | N. 3 Expression of mutated p21 Ras-~ ptides in transfected EBV-Iymphoblasts elicit a strong specific en-response in an autologous | |
Chen | Novel cancer vaccines | |
JP2011102320A (ja) | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン | |
Hiroshi et al. | A Novel Hydrophobized Polysaccharide/Oncoprotein Complex Vaccine for Her2 Gene Expressing Cancer | |
Zhang | LAH4: A novel cell-penetrating peptide for application in tumor immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 526282 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/04411 Country of ref document: ZA Ref document number: 200304411 Country of ref document: ZA Ref document number: PA/a/2003/005032 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002547529 Country of ref document: JP Ref document number: 2431188 Country of ref document: CA Ref document number: 03048137 Country of ref document: CO Ref document number: 887/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037007634 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018215602 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300640 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001999387 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002221519 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037007634 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999387 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 526282 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 526282 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002221519 Country of ref document: AU |